VitalCare Announces National Launch of Diabetes Treatment Centers
National Launch of FDA Approved iCAT Therapy Begins
CARSON CITY, Nev. (Business Wire EON) April 22, 2008 --
VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets: VDTI), a Nevada
Corporation, today announced the national launch for opening licensed
diabetes treatment centers utilizing the micro-dose intravenous insulin
pump technology together with proprietary algorithms and clinical
protocols for providing Intercellular Activation Therapy (iCAT) for
treating diabetes.
The iCAT treatment is currently being administered at several clinics in
Arizona, Nevada, Utah, Florida, Texas and Puerto Rico, to those who
suffer from Type 1 and Type 2 Diabetes, in addition to secondary
complications of Type 2 Diabetes including hypertension, peripheral
vascular disease, retinopathy, heart disease, peripheral neuropathy,
kidney disease, and diabetic wounds.
Jimmy McDougald, CEO, stated, “Due to VitalCare’s
clinical specialists’ succeeding in the
treatment of Type 1, Type 2 and Secondary Complications of Type 2
Diabetes over the past two decades, our executive board has decided to
open opportunities for licensing VitalCare Diabetes Treatment Centers
affiliates with certified training for qualified healthcare providers,
for the licensing and use of iCAT Therapy. It is VitalCare’s
goal to make iCAT Therapy more accessible to the 21 million diabetics in
North America. The VitalCare Diabetes Treatment Centers will either be
company owned, joint ventured or licensed to select qualified medical
professionals.”
About VitalCare Diabetes Treatment Centers, Inc.
VitalCare Diabetes Treatment Centers, Inc. is a publicly traded company
specializing in providing Administrative, Marketing, Business
Development, Strategic Planning, Clinical Oversight and
Clinical Management Services to the Diabetes Healthcare Sector.
VitalCare will become the premier company bringing diabetes related
medical devices and healthcare services direct to consumers, focusing on
the emerging technology and treatment intervention for treating Type 1
and Type 2 Diabetes known as “Intercellular
Activation Therapy (iCAT).”
Safe Harbor Statement: Forward-looking statements in this release with
respect to VitalCare Diabetes Treatment Centers, Incorporated’s
business, financial condition and results of operations, as well as
matters of timing and the prospective terms of the transaction described
are subject to risks and uncertainties that could cause actual results
to differ materially from those expressed in the forward- looking
statements, including, but not limited to, certain delays beyond
VitalCare Diabetes Treatment Centers, Incorporated’s
control with respect to market acceptance of their technology and/or
products, whether financing will be available, the effect of the
application of acquisition accounting policies as well as certain other
risk factors which are and may be detailed from time to time in VitalCare’s
filings with the Securities and Exchange Commission.
Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/WmV0YS1Qcm9mLUNyYXMtTWFnbi1GYWx1LVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
